Cure’s AI Drug Discovery Funding Tracker 2026

The latest biotech venture capital news relating to AI drug discovery, updated monthly—tracking major funding rounds of $10M or more in 2026.

For medtech deals, visit our Medtech Funding Tracker, updated weekly.

October 2026

Pathos AI

Date: October 23 Series: Series E Amount: $237M Therapeutic Area: Oncology (prostate, breast, lung, multiple myeloma), expanding into Alzheimer’s and other neurological disease Modality: Agentic AI platform (Foundry) with thousands of AI agents that synthesize clinical, genomic, and competitive data to select assets, identify likely responders, and guide trial decisions Notable Investors: Bristol Myers Squibb led the round, joined by existing investors including AstraZeneca, NEA, and General Atlantic.

Pathos closed its round at a roughly $3B valuation on the same day it signed two partnerships. Bristol Myers Squibb gets three-year exclusive use of Foundry for its neuroscience programs, and Pathos will pay $55M over five years to license Tempus data for Alzheimer’s work. The capital will advance JSKN016, a TROP2/HER3 bispecific ADC, toward registrational studies, alongside three other clinical assets. Its pipeline spans prostate cancer, multiple myeloma, MET-altered lung cancer, and ER+/HER2- breast cancer.

Warp Sciences

Date: October 22 Series: Series A (as reported) Amount: $215M Therapeutic Area: Multiple (medicinal chemistry services for pharma and biotech discovery programs across therapeutic areas) Modality: Automated, US-based chemistry contract research organization combining chemists, robotics, and AI models trained on lab experiments to synthesize and test molecular variations for drug candidates Notable Investors: Lightspeed led the round, joined by IVP, Premji Invest, Lux Capital, and Mayfield.

Warp Sciences, founded by former OpenAI for Science head Kevin Weil, emerged from stealth at an $865M valuation. It is targeting a drug chemistry step that pharma has long outsourced to firms like WuXi AppTec, starting with producing molecular variations for drug candidates.

September 2026

ai3Bio

Date: September 29 Series: Series A Amount: $48M Therapeutic Area: Autoimmune disease Modality: AI discovery platform paired with two in vivo approaches that eliminate disease-causing Th17 cells: lipid nanoparticle-delivered mRNA (STARx) and a targeting antibody (T Deplete) Notable Investors: UPMC Enterprises and Ziff Capital Partners led as founding investors, joined by Cockrell Interests and Tanis Ventures.

Ai3Bio is targeting pathogenic Th17 cells with the aim of delivering lasting remission in autoimmune disease, using an AI platform to identify a marker shared across conditions. STARx depleted the cells in patient blood samples, and T Deplete showed efficacy in non-human primates. The Series A funds IND-enabling studies.

BigHat Biosciences

Date: September 24 Series: Series C Amount: $75M Therapeutic Area: Oncology (GI tumors), with a broader biologics pipeline Modality: AI protein design platform paired with automated experimentation to engineer antibodies and other biologics, including antibody-drug conjugates and T-cell engagers Notable Investors: DFJ Growth and Premji Invest co-led the round, joined by Catalio Capital Management, LG Technology Ventures, and existing investors including a16z, Amgen Ventures, and Eli Lilly.

BigHat’s round brings its total funding to $223M. It will advance a clinical CDH17-directed ADC (BHB810) for GI tumors and a preclinical T-cell engager (BHB299), while continuing to build out its discovery platform.

Enveda Biosciences

Date: September 23 Series: Series E Amount: $311M Therapeutic Area: Multiple (atopic dermatitis and asthma; metabolic health and post-GLP-1 weight maintenance; inflammatory bowel disease) Modality: AI platform (PRISM) that maps the chemical diversity of natural compounds from plants, microbes, and marine organisms, identifying nature-derived small molecules as drug candidates, paired with an automated wet lab Notable Investors: Catalio Capital Management led the round, joined by ICONIQ, Lightspeed, T. Rowe Price, and existing investors Baillie Gifford and Lux Capital.

Enveda closed its third megaround in as many years, doubling its valuation to roughly $2 billion after positive early results for two of its three PRISM-discovered candidates: ENV-294 (atopic dermatitis/asthma) and ENV-308 (post-GLP-1 weight maintenance). A third, ENV-6946, is in mid-stage IBD trials. Total funding since inception now tops $845M.

Basecamp Research

Date: September 23 Series: Series C Amount: $140M Therapeutic Area: Multiple (initial focus on in vivo cell therapy for cancer and autoimmune disease) Modality: Biological foundation models (EDEN, 28 billion parameters, trained on Basecamp's proprietary Trillion Gene Atlas) that design long, complex DNA sequences paired with specialized enzymes to deliver them, aiming to reprogram a patient's cells inside the body rather than via conventional manufactured cell therapy Notable Investors: S32 led the round, joined by NVIDIA (NVentures), Anthropic's Anthology Fund, and the NATO Innovation Fund.

Basecamp's oversubscribed round values the London startup at $800M, bringing total funding to $225M. Its EDEN models aim to make cell therapy more customizable and skip the costly manufacturing steps of approaches like CAR-T. No clinical trial date disclosed yet. The round also notably pairs two of the biggest names in AI, NVIDIA and Anthropic, as backers of the same biotech bet.

Anew Labs

Date: September 16 Series: External financing following spinout from ByteDance Amount: $290M Therapeutic Area: Multiple (disclosed pipeline includes an IL-17 inhibitor for autoimmune disease, plus undisclosed targets) Modality: AI models for biomolecular structure prediction (AnewFold), molecular and antibody design (AnewDesign), and drug discovery reasoning (AnewMind) Notable Investors: HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment/GL Ventures led the round, with 5Y Capital as co-lead, joined by Gaorong Ventures, Primavera Venture Partners, Boyu Capital, strategic investor SBP Group, and the state-backed Shanghai Future Industries Fund.

Anew Labs, the Shanghai-headquartered AI-for-science unit spun out of TikTok parent ByteDance, closed its first external funding round at a $1.5B post-money valuation, making it one of the best-capitalized private AI drug discovery companies globally at launch. ByteDance retains a 56% stake. The unit traces back to an internal AI4S team formed in 2021 and has already shown early pipeline results, including an AI-designed IL-17 inhibitor presented at a major immunology conference earlier this year.

Tectora Therapeutics

Date: September 9 Series: Series A Amount: $55M Therapeutic Area: Immunology and immune-mediated disease Modality: AI- and physics-based computational drug design (built on Schrödinger's platform) for small-molecule candidates Notable Investors: New Enterprise Associates and RA Capital Management

Tectora Therapeutics launched as a new spinout of Schrödinger, with two early-stage small-molecule programs, SDGR-4594 and SDGR-8139, generated by Schrödinger's computational discovery engine. Its $55M Series A will support continued collaboration with Schrödinger's drug discovery team as the two undisclosed-indication candidates move toward the clinic. The deal is a notable example of an established computational platform spinning out a dedicated company to take its discoveries into clinical development.

Superluminal Medicines

Date: September 3 Series: Series B Amount: $60M Therapeutic Area: Metabolic disease (genetic and hypothalamic obesity); broader pipeline targets GPCRs Modality: AI- and computational chemistry-driven design of small molecules against historically hard-to-drug G protein-coupled receptors (GPCRs) Notable Investors: BVF Partners, Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA (NVentures), Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels

Superluminal Medicines, a Boston-based AI drug discovery company, closed an oversubscribed $60M Series B to advance its lead MC4R agonist into phase 1 trials later this year. The program targets genetic and hypothalamic forms of obesity. The round also adds to a growing pattern of NVIDIA's venture arm backing AI-native small-molecule discovery platforms, following investments in companies including Terray Therapeutics and Proxima. Superluminal will also use the funding to expand its pipeline of purpose-designed molecules targeting other GPCRs.

August 2026

Adaptyv Bio 

Date: August 25 Series: Series A Amount: $40M (€34.35M) Therapeutic Area: Multiple (protein validation for biologics discovery programs; expanding into peptides, ADCs, and degraders) Modality: Automated, AI-native wet lab that synthesizes and tests AI-designed proteins, accessible by API Notable Investors: Highland Europe led the round, joined by existing investors ACE Ventures, byFounders, and Y Combinator. Adaptyv has become a validation stop for the AI protein-design world, counting Chai Discovery, Boltz, Roche, and Novo Nordisk among its customers. The Lausanne startup plans to roughly triple lab capacity by the end of 2026 and open a London site in Q4.

Harell Data

Date: August 17 Series: Seed / launch financing Amount: $15M Therapeutic Area: Multiple (data infrastructure for AI drug discovery programs; initial datasets cover protein-protein binding and T-cell receptor data) Modality: Secure cloud platform and revenue-sharing marketplace connecting proprietary scientific datasets (starting with protein-protein binding and T-cell receptor data) to AI model developers building drug discovery models Notable Investors: Fuse and Cercano Management led the round, with additional undisclosed participants.

Harell Data launched in Bellevue, Washington with $15M, founded by Harlan Robins, scientific founder of Adaptive Biotechnologies. The company is pursuing a different economic model for AI drug discovery: instead of biotechs and academic labs sitting on proprietary datasets they can't easily monetize, Harell offers secure, revenue-sharing cloud compute built on CoreWeave/NVIDIA infrastructure. AI model builders can train on curated datasets while the original data generators receive a share of the revenue. Early data partners include A-Alpha Bio and Adaptive Biotechnologies.

Beyang Therapeutics

Date: August 12 Series: Series A Amount: $30M Therapeutic Area: Multiple (ophthalmology and retinal disease; acute leukemia) Modality: AI and molecular design platform (ExCEED) that combines proprietary databases with computational simulation to design small molecules Notable Investors: Legend Capital and Shanghai Healthcare Capital co-led the round, joined by China Medical System Holdings, and existing investors Root Venture Partners and YuanBio Venture Capital.

Beyang’s lead program is already past Phase 1: BT01001, a small-molecule eye drop for retinal disease. Behind it sits BT01002, a second-generation menin inhibitor for acute leukemia in IND-enabling studies. The Chengdu company will use the Series A to iterate its ExCEED platform and push international R&D and business development.

Infinimmune

Date: August 11 Series: Series A Amount: $75M Therapeutic Area: Immunology and inflammation (atopic dermatitis) Modality: Anthrobody platform screening millions of single human memory B cells for fully human antibodies, guided by GLIMPSE antibody language models Notable Investors: Regeneron Ventures and Playground Global co-led the round, joined by RA Capital Management and existing investor Merck Global Health Innovation Fund. 

Infinimmune is taking two atopic dermatitis antibodies, IFX-101 (anti-IL-22) and IFX-201 (anti-IL-13), toward the clinic in 2027. The Alameda, California company’s Series A follows a March 2026 Merck collaboration worth up to $838M in potential payments.

Aureka Biotechnologies

Date: August 10 Series: Series B Amount: $100M Therapeutic Area: Multiple (internal antibody pipeline includes GPCR-targeted and dual-target biologics) Modality: AI-native biological foundation models paired with closed-loop, lab-in-the-loop wet-lab infrastructure for de novo molecular design, structure modeling, and function prediction Notable Investors: Granite Asia funded the first tranche exclusively, with a subsequent tranche led by an undisclosed strategic investor, joined by HighLight Capital and existing backers Qiming Venture Partners, MPCi, and NRL Capital.

Aureka Biotechnologies, a Laguna Hills, California-based AI-native TechBio company founded in 2023, closed a $100M Series B to fund large-scale training of its next generation of biological foundation models. The round brings its total funding to nearly $200M in under two years. Aureka is building around a "biological world model" thesis: that computation alone isn't enough, and models need continuous experimental feedback from wet-lab programs to improve. The company is already generating differentiated antibodies against hard-to-drug targets such as GPCRs and dual-target biologics.

July 2026

Accipiter Bio

Date: July 31 Series: Seed extension Amount: $10.5M Therapeutic Area: Multiple (oncology and beyond; bispecific-style dual-target biologics) Modality: AI-designed proteins with dual active sites capable of simultaneously binding two targets Notable Investors: Flying Fish Partners and Takeda co-led the round, with Columbus Venture Partners, Cercano Capital, WRF Capital, Alexandria Investments, Pack Ventures, and Argonautic Ventures as existing investors. 

Accipiter Bio, a Seattle-based AI drug developer with roots in the University of Washington's Institute for Protein Design, topped up its seed round in July with an additional $10.5M from existing investors only. It's been less than a year since emerging from stealth with $12.7M in funding. The company will use the funds to grow its team and diversify its clinical portfolio, building on protein-design work that produces molecules with two simultaneous binding sites.

Transcripta Bio

Date: July 22 Series: Series A follow-on Amount: $24M Therapeutic Area: Neurological and neuromuscular disease (Myotonic Dystrophy, FSHD, Autism Spectrum Disorder, Huntington's Disease) Modality: AI-driven transcriptomic signature matching to identify and reposition drugs whose molecular effects reverse patient-derived disease signatures Notable Investors: New Strategic Investors include Mayo Clinic and healthcare investor Omnimed. JAZZ Venture Partners and BlueYard Capital are existing backers who also participated, plus a group of life sciences family offices. 

Transcripta Bio, a Palo Alto-based AI-powered drug discovery company, raised $24M in follow-on funding to its Series A, bringing total disclosed funding to roughly $34M. The capital will fund IND-enabling studies and clinical preparation across its four-program pipeline. The platform pairs a Disease Signature Atlas with Conductor AI, a machine learning system trained on more than a billion gene responses; its furthest-advanced program repositions an FDA-approved oncology drug for a genetically defined ASD subtype.

Chai Discovery

Date: July 14 Series: Series C Amount: $400M Therapeutic Area: Multiple (oncology, immunology, and beyond; partnered programs span several areas) Modality: AI foundation models for molecular design, predicting and reprogramming protein interactions to generate de novo antibodies and small molecules Notable Investors: Index Ventures led the round. Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, and Avra Capital also participated. Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, and General Catalyst are existing backers that re-invested in the Series C round. 

Chai Discovery, an AI company building foundation models to accelerate preclinical drug discovery, raised $400M in Series C financing at a $3.8B valuation, nearly triple its valuation from seven months prior. The company will use the capital to scale its platform and expand partnerships with the pharma industry. Its latest model, Chai-3, builds on Chai-2, the first zero-shot generative platform to achieve double-digit experimental success rates in fully de novo antibody design, with active collaborations already in place with Eli Lilly, Pfizer, and Novartis.

Drug Farm

Date: July 13 Series: Series D (first closing) Amount: $55M Therapeutic Area: Rare genetic disease (ROSAH syndrome), cardiovascular disease, and hepatitis B Modality: AI-developed small-molecule inhibitors, including ALPK1-targeted compounds Notable Investors: Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise co-lead the round. New investors include: Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, and Keyuan Pharma. BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, and Biometas are existing investors that also participated. 

Drug Farm, a China- and US-based AI drug-design specialist, closed the first tranche of a $55M Series D. Proceeds will advance lead candidate DF-003, an AI-developed ALPK1 inhibitor moving into Phase 3 for the rare genetic disorder ROSAH syndrome, alongside proof-of-concept work in atherosclerotic cardiovascular disease and continued development of a second ALPK1 inhibitor for hepatitis B.

Alchemab Therapeutics

Date: July 9 Series: Series A extension Amount: £25M ($34M) Therapeutic Area: Neurodegeneration (ALS) and oncology Modality: AI-enabled antibody discovery platform mining naturally occurring protective antibodies from disease-resilient individuals Notable Investors: British Business Bank was the lead investor. Existing key investors include SV Health Investors, RA Capital Management, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment, and Camford Partners

Alchemab Therapeutics, a London-based clinical-stage biotech, raised a $34M extension to its Series A, bringing the round to roughly £109M (more than $147M) total. The company's Resiliome platform draws on more than half a billion antibody sequences, described as the largest single-source proprietary antibody database in the world, to identify protective antibodies in people naturally resilient to disease. Proceeds will accelerate research, expand the antibody database, and advance two additional wholly owned programs into the clinic.

MindRank AI

Date: July 9 Series: Series B Amount: $52M Therapeutic Area: Multiple (including metabolic disease) Modality: AI-native drug R&D platform integrating biology, chemistry, computation, experimental data, and clinical learning Notable Investors: Institutional and healthcare funds (specific investors not disclosed)

MindRank AI, a clinical-stage biotech developing an AI-native drug R&D engine, raised $52M in Series B financing. The company will use the capital to advance its Molecule Arts Platform (MAP), including its multi-agent system and clinical-data-in-the-loop capabilities, while progressing its pipeline. Its lead program, MDR-001, is an AI-designed oral small-molecule GLP-1 receptor agonist already in Phase III development in China.

June 2026

Xellar Biosystems

Date: June 29 Series: Series A / A+ Amount: $50M Therapeutic Area: Multiple (its platform serves broad drug discovery applications) Modality: AI-driven "3D Bio Intelligence" platform combining organ-on-chip systems, lab automation, high-content imaging, and multi-omics analysis Notable Investors: Investor syndicate not publicly disclosed

Xellar Biosystems, a Boston-based TechBio company, raised $50M in Series A/A+ financing to build out its 3D Bio Intelligence platform. The company integrates organ-on-chip systems with AI-driven biological modeling to generate human-relevant data infrastructure for drug discovery, positioning itself as a data and virtual-cell technology layer rather than a therapeutics developer with its own pipeline.

Waypoint Bio

Date: June 2 Series: Series A Amount: $20M Therapeutic Area: Oncology (solid tumors) Modality: AI-designed in vivo CAR-T therapies using spatial biology, computer vision, and pooled in vivo screening Notable Investors: Amplify Partners was the lead investor. Other investors include General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, and Hummingbird Ventures

Waypoint Bio, an AI-native cell therapy company, raised $20M in Series A financing to advance its lead program, WAY-103, into an investigator-initiated trial expected to begin in late 2026. The company applies computer vision and spatial biology to pooled in vivo screens, aiming to design next-generation CAR-T therapies for solid tumors. In this area, CAR-T has historically struggled outside blood cancers.

May 2026

Perceptic

Date: May 26 Series: Seed  Amount: $12M  Therapeutic Area: Multiple (platform serves pharma R&D broadly)  Modality: End-to-end AI platform spanning drug discovery, asset scouting, indication selection, and clinical trial design  Notable Investors: Accel (lead), Air Street Capital, and Elder Gull

Perceptic, a startup that automates drug discovery from start to finish for Big Pharma, closed $12M in seed funding. According to their press release, Perceptic will focus on scouting external assets developed by biotechnology companies, helping pharma companies choose which indications to pursue in clinical trials, and building a "data foundation" for clinical trial design. Perceptic is headquartered in London and also has a presence in the Switzerland Innovation Park Basel Area.

Isomorphic Labs

Date: May 12  Series: Series B  Amount: $2.1B (brings total funding to roughly $2.7B)  Therapeutic Area: Multiple (internal pipeline focused on oncology and immunology; partnered programs span additional areas)  Modality: AI drug design engine (IsoDDE) spanning small molecules and biologics across multiple modalities  Notable Investors: Thrive Capital (lead), Alphabet and GV (existing), MGX, Temasek, CapitalG, and the UK Sovereign AI Fund

Headquartered in London with a second location in Lausanne, Switzerland, Isomorphic Labs is an AI company founded by Demis Hassabis, who serves as CEO. Isomorphic Labs is an Alphabet-founded firm that plans to use its $2.1B fundraising round to accelerate drug development through AI. It's an AL model, AlphaFold, that predicts protein structures. To date, this is the second-largest fundraising for a biotech company, following Altos Labs' $5.5 billion combined investment.

April 2026

Fathom Therapeutics (formerly Atommap)

Date: April 27  Series: Series A (oversubscribed)  Amount: $47M  Therapeutic Area: Multiple (internal pipeline in high-impact disease areas; lead program includes a protein degrader against an "undruggable" target)  Modality: Physics- and AI-based small-molecule drug design, simulating protein motion at atomic resolution  Notable Investors: Sutter Hill Ventures (lead), Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures

New York-based drug design company, Fathom Therapeutics (formerly Atommap), rebranded and raised a $47M Series A financing round led by Sutter Hill Ventures. Participating investors included Chemistry, Alexandria Venture Investments, and NY Ventures, among others. The company uses physics-based simulations and AI to model protein motion at the atomic level, addressing a long-standing limitation in computational drug discovery, according to its official press release. 

Alloy Therapeutics

Date: April 15  Series: Series E  Amount: $40M (values company at $1B)  Therapeutic Area: Platform / drug discovery infrastructure Modality: AI-powered antibody, bispecific, genetic medicine, and cell therapy discovery infrastructure, plus preclinical/clinical services and biologics manufacturing  Notable Investors: 8VC; JIC Venture Growth Investments; Echo Capital; multiple family offices; existing investors Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, Ulysses Diversified Holdings

Alloy Therapeutics is a company empowering drug discovery and development through AI/ML-driven innovation and integrated solutions. Headquartered in Waltham, Massachusetts, and founded by Errik Anderson, Alley Therapeutics just raised $40M in Series E funding. To date, total capital raised is $174M, with a $1B valuation. Notable investors include 8VC, JIC Venture Growth Investments, and Echo Capital Group. Funding will go towards further scaling its AI-driven biotech infrastructure. 

Helical

Date: April 14  Series: Seed  Amount: $10M  Therapeutic Area: Multiple (deployed programs span neurodegenerative disease, including ALS, cardiovascular disease, and predictive safety biomarkers)  Modality: Application layer that turns biological foundation models into reproducible in-silico drug discovery workflows for target identification, biomarker discovery, and therapeutic design  Notable Investors: redalpine (lead), Gradient, BoxGroup, Frst, and angels, including Aidan Gomez (Cohere) and Clément Delangue 

Helical is a London-based biotech and AI company that provides an application layer for pharmaceutical companies to test biological hypotheses computationally at scale. It replaces physical web lab experiments that are slow with in silico simulations, ultimately helping researchers accelerate drug discovery from years to just a few weeks. The company was founded in 2024 by Rick Schneider, Maxime Allard, and Mathieu Klop. Redalpine led the $10M round, with investors including Gradient, BoxGroup, and Frst. 

Generare

Date: April 2  Series: Series A  Amount: €20M / $23M  Therapeutic Area: Multiple (compounds licensed to pharma/agrochemical partners as discovery starting points, including antimicrobial and oncology applications)  Modality: AI- and synthetic-biology-driven generation of novel small-molecule data mined from microbial genomes, feeding downstream drug-discovery AI models  Notable Investors: Alven and daphni (co-leads), Galion.exe, Teampact Ventures, and VIVES Partners

Generate is a Paris-based startup founded in 2023 that recently raised a €20M ($23M) Series A to scale AI-driven molecular discovery. As reported in the company's press release, Generate identified more than 200 previously uncharacterized molecules last year, which differentiates its platform from other techbio competitors. Generate's current goal is to scale its dataset to more than 2,000 molecules by 2027 and expand its team of experts. 

March 2026

Scala Biodesign

Date: March 31  Series: Series A  Amount: $16M (brings total funding to $21.5M) Therapeutic Area: Multiple (platform serves biologics, enzymes, antibodies, vaccines and industrial biotech programs)  Modality: AI and physics-based computational protein design platform (ScalaOS)  Notable Investors: Grove Ventures (lead), TLV Partners, Deep Insight, and the Israel Innovation Authority

Founded in 2022 by Dr. Ravit Netzer and Dr. Adi Goldenzweig, Scala Biodesign is a Tel Aviv-based company that develops protein-based products using ScalaOS. Scale Biodesign's $16M Series A financing will support their hybrid AI-driven software platform to accelerate the design and optimization of biologics, vaccines, antibodies, and enzymes. Grove Ventures was the lead investor, with TLV Partners, Deep Insight, and the Israel Innovation Authority also participating. 

Earendil Labs

Date: March 20  Series: Financing rounds (not a single named series)  Amount: $787M  Therapeutic Area: Oncology, autoimmune, and inflammatory diseases  Modality: AI-designed antibodies and biologics (bispecifics, T-cell engagers, dual-targeting ADCs)  Notable Investors: Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, Biotech Development Fund (Hillhouse + Pfizer)

AI-powered biotech company Earendil Labs, which integrates machine learning and predictive protein modeling to design next-generation biologics, has raised a combined $787M in financing. Leading global investors included Dimension Capital, DST Global, and INCE Capital, among others, alongside existing and new investors in the healthcare and technology spaces. According to their press release, the financing will accelerate Earendil Labs' AI-driven R&D platform and its growing pipeline of antibody and biologics programs. 

February 2026

Tamarind Bio

Date: February 26  Series: Series A  Amount: $13.6M total raise, including a $12M Series A component  Therapeutic Area: Multiple (platform-agnostic infrastructure serving 8 of the top 20 pharma companies, plus biotechs including Boehringer Ingelheim, Bayer, Mammoth Biosciences, and Adimab)  Modality: Cloud infrastructure for running AI and physics-based molecular models (AlphaFold, RFdiffusion, MPNN, GROMACS, and 200+ others) without local ML/infrastructure setup  Notable Investors: Dimension Capital (lead), and Y Combinator

Based in San Francisco and founded by Stanford computer science alumni Deniz Kavi and Sherry Liu in 2023, Tamarind Bio is a platform for molecular AI inference that serves thousands of leading scientists worldwide. According to Kavi, the company has grown revenue by 7x over the last year, with key partnerships with organizations such as Bayer, Boehringer Ingelheim, and Adimab. Its recent $13.6M in funding includes a $12M Series A round led by Dimension Capital, with Y Combinator among the investors. 

Galux

Date: February 9  Series: Series B  Amount: $29M (brings total funding to $47M)  Therapeutic Area: Multiple (targets include PD-L1, HER2, and expansion into GPCRs and ion channels)  Modality: AI-driven de novo protein and antibody design, generating therapeutic proteins from scratch rather than modifying existing templates  Notable Investors: InterVest, DAYLI Partners, PATHWAY Investment (existing); Yuanta Investment, Korea Development Bank, SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, Mirae Asset Securities

Founded in 2020, Galux is a South Korean biotechnology company that develops AI for drug discovery. The company recently raised $29M Series B funding to advance its AI-driven protein design for drug discovery. With the close of the round, Galux's total funding comes to $47 million. Several existing investors participated in the Series B round, along with new investors such as Yuanta Investment, Korea Development Bank (KDB), and SL Investment. 

January 2026

Proxima (formerly VantAI)

Date: January 13  Series: Seed (oversubscribed)  Amount: $80M  Therapeutic Area: Multiple (AI-driven proximity-therapeutics platform; first partnered program expected to enter the clinic in 2026)  Modality: AI-designed PROTACs and molecular glues (proximity-based small molecules)  Notable Investors: DCVC (lead), NVentures (NVIDIA), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, and Modi Ventures

As part of their recent oversubscribed $80M fundraise, VantAI has rebranded as Proxima to better reflect their focus on unlocking proximity-based therapeutics through technology and data. DCVC led the most recent round of funding, with participation from other investors such as NVentures, Braidwell, Roivant, AIX Ventures, and Yosemite. The AI-native drug discovery company is primarily based in New York City, with a physical presence in Boston, Massachusetts. 

Converge Bio

Date: January 13  Series: Series A  Amount: $25M (brings total funding to $30M)  Therapeutic Area: Multiple (platform serves pharma and biotech clients across target discovery, antibody design, and manufacturing optimization)  Modality: Multi-model AI system for target discovery, antibody design, and protein manufacturing optimization  Notable Investors: Bessemer Venture Partners (lead), TLV Partners, Vintage Investment Partners, Saras Capital, and executives from Meta, OpenAI, and Wiz

Converge Bio, a generative AI life sciences company that accelerates drug development, raised $25M in Series A funding, bringing the total funding to $30M. Bessemer Venture Partners led the round, with other investors including TLV Partners, Vintage Investment Partners, and Saras Capital. Converge Bio plans to expand operations and development. The three co-founders are Dov Gertz, CEO; Oded Kalev, CTO; and Dr. Iddo Weiner, CSO. Converge Bio is headquartered in Boston, Massachusetts, and Tel Aviv, Israel. 

Topos Bio 

Date: January 8  Series: Seed  Amount: $10.5M  Therapeutic Area: Neurodegenerative disease initially (Alzheimer's, Parkinson's), with planned expansion into oncology and metabolic disorders  Modality: AI-native foundation model (Topos-1) for intrinsically disordered proteins, generating dynamic conformational ensembles rather than static structures, paired with generative chemistry for small-molecule design  Notable Investors: Boldstart, Threshold, and Neo; angels including Dara Khosrowshahi (Uber) and Naveen Rao (Unconventional AI)

Topos Bio, an AI-native biotech company that develops drug-discovery platforms for intrinsically disordered proteins (IDPs) raised a $10.5M seed round to target 'undruggable' proteins in Alzheimer's and Cancer. Boldstart, Threshold, and Neo led the funding round, with other angel investors like Dara Khosrowshahi and Naveen Rao participating. Topos Bio is headquartered in San Francisco and was founded by biophysicist and AI leader Ryan Zarcone and former Intel AI CTO Amir Khosrowshahi. 

Boltz

Date: January 8  Series: Seed  Amount: $28M  Therapeutic Area: Multiple (platform-agnostic; deployed for small-molecule and biologics programs across Pfizer's and Takeda's pipelines)  Modality: Open biomolecular foundation models (Boltz-2, BoltzGen) for structure prediction, binding affinity estimation, and de novo protein/small-molecule design, packaged into a hosted product platform with AI-powered discovery agents  Notable Investors: Andreessen Horowitz, Amplify Partners, Zetta Venture Partners (co-leads); angels including Clément Delangue (Hugging Face), Factorial Capital, and Obvious Ventures

AI-driven biotech startup, Boltz, raised a $28M seed funding round led by Zetta Ventures, Amplify Partners, and 16z. Founded in late 2024 by MIT researchers Gabriele Corso, Jeremy Wohlwend, and Saro Passaro, Boltz is partnering with Pfizer on AI drug discovery. Boltz will leverage Pfizer's historical data in its models used to predict molecular structures, as well as small-molecule binding and biologics, per the company's fundraising press release.